IP Library Granted Patent US 11,193,168
Granted Patent B2
US 11,193,168 · App. 16/789,279 · Granted Dec 7, 2021

Multiplex amplification detection assay II

Inventors: Hatim T. Allawi (Middleton, WI); William G. Weisburg (San Diego, CA); Graham P. Lidgard (Middleton, WI); Michael W. Kaiser (Stoughton, WI); Abram M. Vaccaro (Rio, WI); Gracie Shea (Madison, WI)
Assignee: Exact Sciences Development Company, LLC
C12Q1/686C12Q1/6827C01B17/48C12N15/65C12N2310/122C12Q2521/301C12Q2531/113C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,193,168
App. No.
16/789,279
Granted
Dec 7, 2021
Kind
B2
Abstract

Provided herein is technology relating to the amplification-based detection of bisulfite-treated DNAs and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, e.g., plasma samples.

Claims (35)

1. A method of analyzing a sample for multiple target nucleic acids, comprising:

(a) amplifying a sample comprising bisulfite-treated DNA by PCR in a single reaction using a plurality of different primer pairs to produce a pre-amplified mixture;

(b) partitioning the pre-amplified mixture into a plurality of different detection assay reaction mixtures, wherein each detection assay reaction mixture comprises a portion of said pre-amplified mixture; and

(c) conducting a plurality of detection assays on the detection assay reaction mixtures, wherein the detection assays are PCR-flap assays that employ flap oligonucleotides that have a target-specific region of at least 13 bases in length and an additional amount of a primer pair selected from said plurality of different primer pairs of step (a), wherein the primer pair selected is not a nested primer pair or a semi-nested primer pair.

2. The method of claim 1 , wherein one or more of the flap oligonucleotides used in (c) has a target-specific region comprising one or more nucleotides that are capable of making non-Watson-Crick base pairs.

3. The method of claim 1 , wherein one or more of the flap oligonucleotides used in (c) has a target-specific region having a length in the range of 13 to 30 bases.

4. The method of claim 1 , wherein the one or more of the flap oligonucleotides used in (c) has a target-specific region that has a T m in the range of 60° C. to 70° C. and the detection assays comprise a denaturation step at least 90° C., an annealing step at a temperature that is in the range of 60° C. to 70° C., and an extension step at a temperature in the range of 65° C. to 75° C.

5. The method of claim 1 , wherein said bisulfite treated DNA is from a human subject.

6. The method of claim 5 , wherein said sample is prepared from a body fluid.

7. The method of claim 6 , wherein said body fluid comprises plasma.

8. The method of claim 7 , wherein the sample is prepared from cell-free DNA isolated from plasma.

9. The method of claim 8 , wherein said cell-free DNA is less than 200 base pairs in length.

10. The method of claim 8 , wherein said cell-free DNA is isolated from said plasma by a method comprising:

a) combining the plasma sample with:

i) protease; and

ii) a first lysis reagent, said first lysis reagent comprising

guanidine thiocyanate; and

non-ionic detergent;

to form a mixture wherein proteins are digested by said protease;

b) to the mixture of step a) adding

iii) silica particles, and

iv) a second lysis reagent, said second lysis reagent comprising:

guanidine thiocyanate;

non-ionic detergent; and

isopropyl alcohol;

under conditions wherein DNA is bound to said silica particles;

c) separating silica particles with bound DNA from the mixture of b);

d) to the separated silica particles with bound DNA adding a first wash solution, said first wash solution comprising guanidine hydrochloride or guanidine thiocyanate and ethyl alcohol;

e) separating the silica particles with bound DNA from said first wash solution;

f) to the separated silica particles with bound DNA adding a second wash solution, said second wash solution comprising a buffer and ethyl alcohol;

g) separating washed silica particles with bound DNA from said second wash solution; and

h) eluting DNA from the washed silica particles with bound DNA.

11. The method of claim 10 , wherein said protease is Proteinase K.

12. The method of claim 6 , wherein the sample is prepared from at least one mL of bodily fluid.

13. The method of claim 1 , wherein the pre-amplified mixture is partitioned into at least 4 detection assay reaction mixtures.

Assignments (4)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS (REEL/FRAME 69898/0249) Recorded Mar 27, 2026
From: JPMORGAN CHASE BANK, N.A.
To: EXACT SCIENCES CORPORATION
Reel/Frame 075288/0393 →
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: EXACT SCIENCES CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0249 →
MERGER Recorded Nov 8, 2022
From: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
To: EXACT SCIENCES CORPORATION
Reel/Frame 061692/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2020
From: ALLAWI, HATIM T.; WEISBURG, WILLIAM G.; LIDGARD, GRAHAM P.; KAISER, MICHAEL W.; VACCARO, ABRAM M.; SHEA, GRACIE
To: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
Reel/Frame 051816/0435 →
Continuity (2)
Continuation 15841006 · Dec 13, 2017
Related Publication 20200248233A1 · Aug 6, 2020
Cited By (1)
US 12,297,510